Ahmet Unsal

Dr. Ahmet Unsal

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Clinics
Verified
Journal Article
Open access
PDF file
SASüleyman Ahbab
Süleyman Ahbab
AUAhmet Unsal
Ahmet Unsal
HAHayriye Esra Ataoğlu
Hayriye Esra Ataoğlu
TCTuba Selçuk Can
Tuba Selçuk Can
DKDerya Kayaş
Derya Kayaş
YSYıldıray Savaş
Yıldıray Savaş
Nonalcoholic fatty pancreas disease (NAFPD) is characterized by excessive fat deposition in the pancreas in the absence of alcohol consumption. In this study, we aimed to detect a possible relationship between adipose tissue accumulation, prediabetes and diabetes. This cross-sectional and retrospective study included 110 patients. Three groups were classified as controls, patients with prediabetes and patients with type 2 diabetes. The abdominal computed tomography (CT) attenuation measurement results of the pancreas were evaluated independently by two experienced radiologists. CT measurements and biochemical parameters were compared between study groups. The relationship between continuous variables was assessed by using one-way ANOVA. To determine the changes in the dependent variable for the effects on study groups, the independent variable was adjusted using ANCOVA. A p-value less than 0.05 was considered statistically significant. The presence of prediabetes and type 2 diabetes was correlated with a decrease in the mean Hounsfield Unit (HU) value of the pancreas (p=0.002). Age was determined to be an independent risk factor and was correlated with NAFPD (p=0.0001). When compared to the controls (p=0.041), 71% of patients with prediabetes and 67% of patients with type 2 diabetes were observed to have an increased incidence of NAFPD. Decreased serum amylase was found to be correlated with the mean HU value of the pancreas (p=0.043). NAFPD was independently correlated with both prediabetes and type 2 diabetes adjusted for age (p=0.0001) in this study. Additionally, age was determined to be an independent risk factor and was correlated with NAFPD.

27 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
STSalih Tunbekici
Salih Tunbekici
HYHaydar Çağatay Yüksel
Haydar Çağatay Yüksel
CACaner Acar
Caner Acar
GŞGökhan Şahin
Gökhan Şahin
SOSeval Orman
Seval Orman
PGPınar Gürsoy
Pınar Gürsoy
Background/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18–67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23–2.75) and a median overall survival of 4.1 months (95% CI: 3.52–4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p = 0.022). Progression-free survival was longer in patients with ECOG 0–1 than in those with ECOG 2 (p = 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies.

17 November 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
STSalih Tunbekici
Salih Tunbekici
GŞGökhan Şahin
Gökhan Şahin
HYHaydar Çağatay Yüksel
Haydar Çağatay Yüksel
CACaner Acar
Caner Acar
IAImge Akın
Imge Akın
EGERDEM GOKER
ERDEM GOKER
Background Uterine leiomyosarcoma is a rare and aggressive malignancy with limited responsiveness to standard therapies. We conducted a real-world, multicenter study to compare the clinical efficacy and safety of two commonly used first-line chemotherapy regimens—doxorubicin–ifosfamide and gemcitabine–docetaxel—in patients with metastatic uterine leiomyosarcoma. Methods This retrospective cohort included 271 patients with advanced or metastatic uterine leiomyosarcoma treated between 2010 and 2023 across 30 centers in Turkey. Patients received either doxorubicin–ifosfamide (n = 142) or gemcitabine–docetaxel (n = 129) as first-line therapy. The primary endpoint was overall survival; secondary endpoints included progression-free survival, objective response rate, disease control rate, and safety. Adverse events were graded according to the Common Terminology Criteria for Adverse Events version 5.0, while survival outcomes were estimated using the Kaplan–Meier method and further analyzed with Cox proportional hazards models. Results Median overall survival was 19.7 months with doxorubicin–ifosfamide and 20.2 months with gemcitabine–docetaxel (P = .26). Median progression-free survival was 5.5 months with doxorubicin–ifosfamide and 7.0 months with gemcitabine–docetaxel (P = .62). The objective response rate was numerically higher with gemcitabine–docetaxel (35% vs. 26%), although not statistically significant (P = .11). Grade 3–4 neutropenia (16% vs. 12%) and febrile neutropenia (7% vs. 6%) were more frequent with doxorubicin–ifosfamide. Conclusions In this largest-to-date real-world cohort of metastatic uterine leiomyosarcoma, doxorubicin–ifosfamide and gemcitabine–docetaxel demonstrated comparable survival outcomes. Gemcitabine–docetaxel, however, was associated with a more favorable hematologic safety profile. These findings support the clinical utility of both regimens while underscoring the need for prospective, biomarker-driven studies to refine treatment selection and improve personalization in this rare malignancy.

1 September 2024 in American Journal of Therapeutics
Verified
Journal Article
Closed access
TKTanju Kapagan
Tanju Kapagan
NBNilufer Bulut
Nilufer Bulut
AUAhmet Unsal
Ahmet Unsal
GEGokmen Umut Erdem
Gokmen Umut Erdem

7 April 2025 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
NANargiz Majidova Altuntash
Nargiz Majidova Altuntash
SYSendag Yaslikaya
Sendag Yaslikaya
MMMartin Mildanoğlu
Martin Mildanoğlu
ACAlper Coskun
Alper Coskun
DUDuygu Ercan Uzundal
Duygu Ercan Uzundal
OKOsman Köstek
Osman Köstek
Background/Aims: The treatment of hepatocellular carcinoma (HCC), which accounts for 90% of all liver cancers, is highly varied. The use of second-line treatments following progression on first-line atezolizumab and bevacizumab (Atez/Bev) for advanced HCC remains controversial. The aim of this study was to analyze the real-world clinical results of second-line treatments in progression after Atez/Bev and to determine the factors affecting prognosis. Materials and Methods: Fifty-eight patients treated with second-line sorafenib, regorafenib, and cabozantinib for progression after first-line Atez/Bev for advanced/metastatic HCC from 20 centers in Türkiye between October 2020 and June 2024 were retrospectively analyzed. Responses were evaluated by Response criteria, specifically Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria. Median overall survival (OS) and progression-free survival (PFS) were computed with the Kaplan–Meier method. The Cox regression model was utilized to analyze multivariate analyses. Results: About 82.8% of the patients were male and the median age of the whole group was 62 (range, 18-78) years. All patients progressed after first-line Atez/Bev and were given second-line treatment. The most commonly used second-line treatment option was sorafenib (70.7%), followed by regorafenib (12.1%) and cabozantinib (10.3%). Both median PFS (4.1 months) and median OS (7.8 months) were longer in patients treated with sorafenib compared to other treatments. In univariate analyses, Child–Pugh score B, alpha-fetoprotein (AFP) levels (>200 ng/mL), extrahepatic spread, and Prognostic Nutritional Index (PNI) < 47.6 substantially raised the risk of overall mortality. Multivariate analysis showed that extrahepatic spread (HR (Hazard ratio): 0.41, P = .012), PNI level (HR: 0.24, P =.005), and AFP level (HR:1.97, P = .049) were independent predictors of OS. Conclusion: Although second-line therapies after Atez/Bev show different degrees of efficacy, survival rates are consistent with the literature. Extrahepatic spread, AFP level, and PNI level are the main prognostic factors. In light of this information, personalized treatment strategies may improve outcomes for this challenging patient group. Cite this article as: Majidova N, Yaslıkaya S, Mıldanoglu MM, et al. Efficacy of second-line treatments after atezolizumab and bevacizumab in advanced hepatocellular carcinoma and related prognostic factors: A multicenter study by the turkish oncology group (TOG). Turk J Gastroenterol. 2025;36(5):293-301.

18 November 2022
Verified
Book Chapter
Closed access
AUAhmet Unsal
Ahmet Unsal
Medulloblastom, çocukluk çağının en sık karşılaşılan malign beyin tümörü olup santral sinir sisteminin agresif ve yüksek dereceli (Evre 4) embriyonel tümörleri arasında sınıflandırılmaktadır. Genellikle serebellum veya dördüncü ventrikül çevresinde lokalize olan bu tümör, anatomik yerleşimi nedeniyle obstrüktif hidrosefaliye yol açarak baş ağrısı, bulantı ve ataksi gibi intrakranial basınç artışı semptomlarıyla klinik olarak prezente olur. Teşhis ve evreleme süreçlerinde detaylı nörolojik muayenenin yanı sıra kontrastlı manyetik rezonans görüntüleme (MRG) ve beyin omurilik sıvısı (BOS) sitopatolojisi hayati önem taşımaktadır. Histopatolojik olarak klasik, desmoplastik/nodüler, yaygın nodülariteli ve büyük hücreli/anaplastik varyantlara ayrılan hastalık; günümüzde gen ekspresyon profillerine göre WNT-aktif, SHH-aktif, Grup 3 ve Grup 4 olmak üzere dört ana moleküler alt grupta incelenir. Bu moleküler sınıflama, hastaların risk stratifikasyonunu belirlemede en belirleyici faktör olup WNT grubu mükemmel bir prognoza işaret ederken, nüks ve metastaz eğilimi yüksek olan Grup 3 en kötü prognoza sahiptir. Tedavi yönetiminde temel strateji, maksimal güvenli cerrahi rezeksiyonu takiben kraniyospinal radyoterapi ve sistemik kemoterapiden oluşan kombine modalitelerin uygulanmasıdır. Güncel teknolojik gelişmeler ve risk gruplarına göre optimize edilen kemoradyoterapi rejimleri sayesinde uzun süreli sağkalım oranlarında kayda değer başarılar elde edilse de, tedavi sonrasında gelişebilecek geç dönem nörotoksik komplikasyonların yönetimi kritik bir önem arz etmektedir. Medulloblastoma is the most prevalent malignant brain tumor in children, categorized as an aggressive, high-grade (Grade 4) embryonal tumor of the central nervous system. Primarily localized within the cerebellum or the fourth ventricle, its proximity frequently causes obstructive hydrocephalus, presenting clinically with symptoms of increased intracranial pressure such as headache, vomiting, and ataxia. Diagnostic and staging protocols heavily rely on comprehensive neurological examinations, contrast-enhanced magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) cytopathology to detect leptomeningeal dissemination. Histopathologically differentiated into classic, desmoplastic/nodular, extensively nodular, and large cell/anaplastic variants, contemporary medicine classifies the disease into four major molecular subgroups based on gene expression: WNT-activated, SHH-activated, Group 3, and Group 4. This molecular stratification serves as a pivotal prognostic determinant, where the WNT subgroup demonstrates an excellent survival outcome exceeding ninety percent, whereas Group 3 exhibits a highly aggressive metastatic nature and the poorest prognosis. The cornerstone of therapeutic management involves a multidisciplinary approach encompassing maximal safe surgical resection followed by craniospinal irradiation and adjuvant systemic chemotherapy. Although advanced surgical techniques and risk-adapted chemoradiotherapy regimens have remarkably improved long-term survival rates to approximately seventy-five percent, mitigating late-term toxic complications and preserving the quality of life remain critical challenges in patient survivorship.